In a recent study involving 590 women with different types of malignancies including nonepithelial and epithelial ovarian cancers, malignancies metastatic to the ovary, other pelvic cancers, and borderline tumors, Ova1 demonstrated higher sensitivity compared to physician's assessment or to CA125 profile and identified the risk of malignancies when combined with physician assessment before surgery. Here, MUC16 is linked to ovarian carcinoma.